Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Joseph Conti

Urology Indiana, PA Medical Doctor

NPI 1073585089 CMS profile 1077082

1265 Wayne Ave, Ste 103, Indiana, PA 15701

Open in the dashboard

General payments

$1,978

111 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Joseph Conti of Indiana, PA is reported in the CMS Open Payments database as having received $1,978 across 111 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 43rd percentile of Urology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $217 9
2024 General $279 16
2023 General $294 15
2022 General $317 19
2021 General $417 26
2020 General $281 13
2019 General $174 13

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Joseph Conti
  • Urology median
  • Middle half of Urology
  • National median

In program year 2025, general payments to Joseph Conti were reported at $217. Among 9,461 Urology profiles paid that year, the median was $629 and the middle half received between $190 and $1,620.

Show as a table
Year Joseph Conti Urology median Middle half National median
2019 $174 $480 $147–$1,201 $163
2020 $281 $246 $87–$645 $114
2021 $417 $358 $111–$1,000 $132
2022 $317 $476 $143–$1,263 $149
2023 $294 $560 $168–$1,461 $160
2024 $279 $563 $170–$1,464 $164
2025 $217 $629 $190–$1,620 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Astellas Pharma US Inc $1,044 58 payments
  2. Ferring Pharmaceuticals Inc. $149 9 payments
  3. Cumberland Pharmaceuticals, Inc. $136 8 payments
  4. Urovant Sciences Inc $125 7 payments
  5. Boston Scientific Corporation $78 4 payments
  6. Janssen Biotech, Inc. $78 4 payments
  7. Sumitomo Pharma America, Inc. $68 4 payments
  8. C. R. Bard, Inc. & Subsidiaries $66 3 payments
  9. NeoTract Inc. $38 2 payments
  10. Pfizer Inc. $36 2 payments
  11. Other $160 10 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $1,870 108 payments
  2. Education $109 3 payments
Products named General payments · program years 2019–2025
  1. MYRBETRIQ $829 49 payments
  2. XTANDI $444 27 payments
  3. GEMTESA $192 11 payments
  4. ADSTILADRIN $138 8 payments
  5. ERLEADA $78 4 payments
  6. CALDOLOR Anesthesiology Pain Management $51 3 payments
  7. CALDOLOR Anesthesiology Pain Management $50 3 payments
  8. AMS 700 $41 1 payment
  9. UROLIFT $38 2 payments
  10. Caldolor Anesthesiology (Pain Management) $35 2 payments
  11. Other $274 17 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 13 drugs

Part D claims

542

Median for Urology: 1,053

Drug cost

$52,239

Median for Urology: $101,464

Branded share of claims

35.6%

Median for Urology: 27.1%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Myrbetriq Mirabegron Brand 49 $39,013
Micafungin Micafungin Sodium Brand 17 $4,180
Tamsulosin Hcl Generic 156 $4,129
Solifenacin Succinate Generic 27 $1,325
Silodosin Generic 14 $815
Finasteride Generic 40 $704
Alfuzosin Hcl Er Alfuzosin Hcl Brand 19 $582
Ampicillin Sodium Generic 16 $468
Dutasteride Generic 18 $453
Levofloxacin Generic 78 $232

The 10 drugs with the highest cost, of 13 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 10,221 Part D prescribers listed as Urology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 52 billing codes

Paid by Medicare

$66,354

Medicare's payments for the services billed

Medicare patients

251

Average age 76

Services billed

1,213

71 women, 180 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 47%
Diabetes 36%
Ischemic heart disease 29%
Depression 25%
Chronic kidney disease 22%
Cancer 19%
Atrial fibrillation 18%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 6 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
ADSTILADRIN
  • Ferring Pharmaceuticals Inc. $79
$79 — —
MYRBETRIQ
  • Astellas Pharma US Inc $75
$75 49 —
ERLEADA
  • Janssen Biotech, Inc. $16
$16 — —
CALDOLOR
  • Cumberland Pharmaceuticals, Inc. $14
$14 — —
XTANDI
  • PFIZER INC. $11
$11 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 6 in the dashboard with a free account

Records

111 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Urology in Pennsylvania

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record